Key Product Details

Species Reactivity

Human, Mouse, Rat

Applications

Flow Cytometry, Immunoprecipitation

Label

Unconjugated

Antibody Source

Monoclonal Armenian Hamster IgG Clone # LG.7F9

Format

BSA Free

Concentration

0.5 mg/ml

View all CD27/TNFRSF7 Antibodies »

Product Specifications

Immunogen

The immunogen for this antibody was CD27.

Reactivity Notes

This antibody is reactive to Mouse, Rat, Human.

Clonality

Monoclonal

Host

Armenian Hamster

Isotype

IgG

Scientific Data Images for CD27/TNFRSF7 Antibody (LG.7F9) - BSA Free

Flow Cytometry: CD27/TNFRSF7 Antibody (LG.7F9) - BSA Free [NBP1-43428]

Flow Cytometry: CD27/TNFRSF7 Antibody (LG.7F9) - BSA Free [NBP1-43428]

Flow Cytometry: CD27/TNFRSF7 Antibody (LG.7F9) [NBP1-43428] - Analysis using the FITC conjugate of NBP1-43428. Staining of C57BL/6 splenocytes with Anti-Human/Mouse CD45R (B220) APC and 0.25 micrograms of Armenian Hamster IgG Isotype Control FITC (left) or 0.25 micrograms of Anti-CD27 FITC (right).
Flow Cytometry: CD27/TNFRSF7 Antibody (LG.7F9) - BSA Free [NBP1-43428]

Flow Cytometry: CD27/TNFRSF7 Antibody (LG.7F9) - BSA Free [NBP1-43428]

Flow Cytometry: CD27/TNFRSF7 Antibody (LG.7F9) [NBP1-43428] - Staining of mouse splenocytes with 0.25 ug Hamster IgG Isotype Control Purified (open histogram) or 0.25 ug Anti-CD27 Purified (filled histogram) followed by Anti-Armenian Hamster IgG FITC . Total viable cells were used for analysis.

Applications for CD27/TNFRSF7 Antibody (LG.7F9) - BSA Free

Application
Recommended Usage

Flow Cytometry

1:10-1:1000

Immunoprecipitation

1:10-1:500
Application Notes
The LG.7F9 antibody has been tested by flow cytometric analysis of mouse splenocyte cell suspensions. This can be used at less than or equal to 0.5 ug per test. Cell number should be determined empirically but can range from 10^5to 10^8cells/test.

Formulation, Preparation, and Storage

Purification

Protein A or G purified

Formulation

PBS (pH 7.2)

Format

BSA Free

Preservative

0.09% Sodium Azide

Concentration

0.5 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C. Do not freeze.

Background: CD27/TNFRSF7

CD27, also referred to as tumor necrosis factor receptor superfamily, member 7 (TNFRSF7), is a type I transmembrane glycoprotein that functions as a co-stimulatory T cell receptor and is expressed on the surface of T cells, natural killer (NK) cells, and B cells (1,2). The human CD27 protein is 260 amino acids (aa) in length and consists of a 19 aa signal sequence, 172 aa extracellular domain (ECD) containing three characteristic cysteine-rich domains (CRDs), a 21 aa helical transmembrane region, and a 48 aa cytoplasmic tail domain (3,4). The CD27 protein has a theoretical molecular weight (MW) of 29 kDa, but is typically is closer to 50-55 kDa due to N-linked and O-linked glycosylation (3). Mouse CD27 cDNA encodes a 250 aa protein with a theoretical molecular weight of 28 kDa (5). Human CD27 shares ~64% aa sequence identity with mouse CD27 protein.

Membrane-bound CD27 is expressed as a disulfide-linked homodimer (3). CD27 binds to the ligand CD70, a transmembrane glycoprotein that is transiently expressed on activated immune cells such as antigen presenting cells (APCs), dendritic cells (DCs), NK cells, B cells, and T cells (1,2,6,7). The receptor-ligand binding interaction leads to NFkappaB and c-Jun pathway activation which promotes immune stimulation and activation and survival of CD4+ T cells, CD8+ T cells, memory T cells, and NK cells (2,6,7). Both CD27 and CD70 are often abnormally expressed or dysregulated on malignant and cancer cells leading to immune evasion and tumor progression (7). CD27 has become a target of interest of immunotherapies for viral infections, autoimmune disease, and cancer (2). Varlilumab, an agonistic CD27 monoclonal antibody (mAB), has entered clinical trials for the treatment of hematological and solid tumor cancers (1,6). Additional clinical trials are in process that combine varlilumab with other immune checkpoint inhibitors like the programmed cell death protein-1 (PD-1) blocking mAb nivolumab (1,2). Initial results are promising, suggesting that targeting CD27, especially in combination with other therapeutics, may be a promising and effective immunotherapy for a variety of pathologies (1,2,6).

References

1. Starzer AM, Berghoff AS. New emerging targets in cancer immunotherapy: CD27 (TNFRSF7). ESMO Open. 2020;4(Suppl 3):e000629. https://doi.org/10.1136/esmoopen-2019-000629

2. Grant EJ, Nussing S, Sant S, Clemens EB, Kedzierska K. The role of CD27 in anti-viral T-cell immunity. Curr Opin Virol. 2017;22:77-88. https://doi.org/10.1016/j.coviro.2016.12.001

3. Buchan SL, Rogel A, Al-Shamkhani A. The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy. Blood. 2018;131(1):39-48. https://10.1182/blood-2017-07-741025

4. Uniprot (P26842)

5. Uniprot (P41272)

6. van de Ven K, Borst J. Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential. Immunotherapy. 2015;7(6):655-667. https://doi.org/10.2217/imt.15.32

7. Flieswasser T, Van den Eynde A, Van Audenaerde J, et al. The CD70-CD27 axis in oncology: the new kids on the block. J Exp Clin Cancer Res. 2022;41(1):12. https://doi.org/10.1186/s13046-021-02215-y

Alternate Names

CD27, TNFRSF7

Gene Symbol

CD27

Additional CD27/TNFRSF7 Products

Product Documents for CD27/TNFRSF7 Antibody (LG.7F9) - BSA Free

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for CD27/TNFRSF7 Antibody (LG.7F9) - BSA Free

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.